Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012245 | 0.88 | MAPT (0.34) | KDM4EMAPTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL16168628 | 0.80 | MAPT (0.36) | KDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL2012033 | 0.80 | MAPT (0.36) | MAPTPOLBTSHRALDH1A1HTT | |
| SCHEMBL2014175 | 0.78 | MAPT (0.35) | MAPTLMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL2019086 | 0.76 | ALDH1A1 (0.38) | KDM4EMAPTLMNAGAAPOLB | |
| SCHEMBL2013201 | 0.74 | ELANE (0.33) | MAPTPOLBSMN1; SMN2 | |
| SCHEMBL12805696 | 0.73 | MAPT (0.33) | MAPTPOLBALDH1A1 | |
| SCHEMBL2013918 | 0.73 | MAPT (0.40) | MAPTLMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL2014705 | 0.73 | MAPT (0.43) | KDM4EMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL2010964 | 0.70 | MAPT (0.38) | KDM4EMAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513069-B1 | ANTIFUNGAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-10-15 | — | — | EP | claimed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | claimed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | claimed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | claimed |
| EP-2513069-B1 | ANTIFUNGAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | ERG28, DPM1, CYP51A1 | KDM4E 3907/4885MAPT 809/4885LMNA 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.